A Molecular Biology And Phase II Study Of Lapatinib (GW572016) In Pediatric Patients With Recurrent Or Refractory Medulloblastoma, Malignant Glioma Or Ependymoma.

Trial Profile

A Molecular Biology And Phase II Study Of Lapatinib (GW572016) In Pediatric Patients With Recurrent Or Refractory Medulloblastoma, Malignant Glioma Or Ependymoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Astrocytoma; Brain cancer; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Medulloblastoma; Oligodendroglioma; Primitive neuroectodermal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2012 Actual patient number changed from 42 to 52 as reported by ClinicalTrials.gov.
    • 10 Nov 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top